fraction was Ն0. 35 , but in this study, ICD implantation rate was half in patients with asymptomatic VT compared with other arrhythmia categories (27% in patients with asymptomatic VT, 53% in patients with VF, and 58% in patients with syncope and inducible arrhythmia), suggesting a more benign prognosis for asymptomatic VT. 6 Moreover, no data on SCD and arrhythmia recurrence were given in this study, Finally, total mortality should be distinguished from arrhythmiarelated mortality, which is all that can be decreased by the ICD. Although total mortality is the most important outcome variable for population studies, it should not be ignored that most of these patients have severe ventricular damage and may succumb to pump failure, which could be a "confounding variable" when one tries to evaluate the results of an antiarrhythmic intervention. Terminal VT in the setting of end-stage heart failure should not be considered a sudden cardiac arrest because the event must be unexpected. Moreover, the efficacy of an ICD in such instances may be limited. Such patients make up much of the group of patients in whom death occurs with VT despite ICD therapy (successful or unsuccessful). 7 The study by Sarter et al 8 is one of the few studies that analyzed the SCD rate in patients with stable post-MI VT. This retrospective cohort of 124 patients with a mean LV ejection fraction of 0.31 who were followed up for a mean of 36 months received electrophysiologically guided therapy with either antiarrhythmic drugs or arrhythmia surgery. In an actuarial analysis, the cumulative rate for total mortality was 32Ϯ5% at 3 years. However, the cumulative rate for SCD in the same period was 7Ϯ3%, with an average annual SCD rate of 2.4%. Brugada et al 9 reported that in a cohort of 140 patients with post-MI VT followed up for a mean of 2 years and treated with antiarrhythmic drugs, the SCD rate was 2%. In contrast, Olson et al 10 found a high SCD rate of 25% over a mean follow-up of 19 months in 122 patients with sustained VT treated with amiodarone (51 of those had tolerated VT and a 25% SCD rate). In the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM), an intermediate 14% risk of SCD at 1 year was found. 11 A more recent study analyzed the outcome of patients in the AVID Registry according to whether their index arrhythmia was stable or unstable VT. 12 The authors found that total mortality at 3 years was 33.6% in patients with stable VT compared with 27.6% in patients with unstable VT. Despite the fact that no further attempt was made to classify the cause of death, the authors suggested that stable VT may be a marker for faster, poorly tolerated VT and thus for SCD; ie, stable VT is not a benign rhythm. However, it is interesting to note that total mortality at 3 years was virtually identical to that in the study by Sarter et al (33.6% versus 32%). 8 Because in the population reported by Sarter et al the SCD rate was low despite a high total mortality, it is difficult to assume what the SCD rate might have been in the AVID Registry population. In addition, in patients receiving an ICD in the AVID Registry, total mortality was as high as 23% (in the total VT group; no information was provided for the specific group of stable VT). 12 A similar phenomenon was observed in our surgical ablative cohort at the University of Pennsylvania (see below) in whom the 5-year mortality was almost 45% but the incidence of SCD was only 4% over the same time period (MEJ, unpublished observations, 1978 (MEJ, unpublished observations, -1992 . Because most of these series reflect data from the 1980s, one could question whether this information applies to our contemporary patients, most of them revascularized and treated with modern pharmacological therapy for LV dysfunction. While recognizing that no answer to this issue can be complete and that tolerated VT may be less frequent in recent years, both the AVID Registry 12 and 2 recent ICD contemporary series 13, 14 suggest that tolerated (slow) VT may still be a clinical problem. It is likely that a specific substrate is required for monomorphic VT, and although it may be less frequent in recent years, once a patient develops monomorphic VT, his/her substrate is similar to what was found in VT patients years ago.
Thus, although it is clear that post-MI tolerated VT carries a high mortality, the contribution of arrhythmic death is unknown but likely far less than suspected. Tolerated VT also can be a clinical problem in the setting of ICD therapy because it can be symptomatic even if it is slow enough to overlap with sinus or supraventricular arrhythmia rates. 13, 14 
ICD Therapy as a Surrogate for Sudden Arrhythmic Death
ICDs provide information about their therapeutic interventions. The notion that this information could establish the natural history of ventricular tachyarrhythmias is an old wish.
In the initial ICD studies, it was thought that if an ICD discharged and the discharge was preceded by symptoms, an arrhythmia had appeared that would have been lethal had the ICD not been implanted. 15 When technological advances allowed the storage and subsequent recording of electrograms preceding ICD therapies, it became clear that some of these therapies were in fact triggered by nonlethal supraventricular arrhythmias. 16 Admitting that electrogram analysis allowed precise differentiation between supraventricular and ventricular tachyarrhythmias, 16 "real" ventricular arrhythmias were considered to measure the degree of protection conferred by the ICD. However, it is quite clear that sustained VT cannot be equated with SCD, so some qualification to electrogram analysis was needed in addition to tachycardia origin to consider an ICD arrhythmia a surrogate for SCD. Bocker et al 17 reported on a retrospective group of 50 patients with hemodynamically tolerated VT treated with an ICD. During a mean follow-up of 17 months, 11 patients (22%) had VT with a cycle length Ͻ250 ms. 17 It was postulated that such fast VT would have been lifethreatening, and a supposed survival benefit in these patients was postulated by subtracting survival free of fast VT from total mortality, giving 27% at 4 years. 17 In a more recent study, with a larger retrospective series of 82 patients with stable VT and a longer follow-up of 23 months, it also was found that a significant number of patients (10 of 82, 12%) developed a VT that was considerably faster than the index VT and was regarded as an unstable VT. 18 The authors came to a 4-year actuarial estimation of developing an unstable VT of 25%. It is of note, however, that the criteria used in this study to consider that the ICD recordings represented an unstable VT were different and less strict that those used in the previous study, pointing out that any ICD criteria for stability of a VT are arbitrary. Moreover, if the criteria of Bocker et al (even less strict) were applied in the latter study, the number of patients with unstable VT would be only 5 (6%) 18 and the ICD benefit much less. Both of these studies fail to provide information about the clinical situation of the patients at the time of the unstable VT (ie, whether they were hospitalized or clinically decompensated).
Several limitations exist to using ICD electrograms as surrogates for SCD and spontaneous ventricular arrhythmias. First, what was going to be a nonsustained VT would be classified as sustained if the device provides therapy; in fact, it has been suggested that ICD therapy frequently can be caused by nonsustained VT. 19 Second, VT tolerance is a complex issue, and rate is only one of the determinants. 20 In our own series of 243 patients with spontaneous tolerated VT and coronary artery disease at the University Hospital Gregorio Marañon, 46 (19%) had a VT cycle length Ͻ270 ms, and 32 (13%) had a VT cycle length Ͻ250 ms (JA and Mercedes Ortiz, PhD, unpublished observations, 2000), so at least 13% of tolerated VT would have been classified as SCD if an ICD were in place, attesting to the complexity of the mechanisms influencing VT tolerance. A third limitation is ICD-related proarrhythmia, in which the ICD can induce, facilitate, or aggravate ventricular arrhythmias by several mechanisms, usually described in observational studies [21] [22] [23] [24] [25] [26] [27] ( Figure 1 ). Although the incidence of each of these mechanisms in unknown, they clearly limit the assumption that ICD-observed arrhythmias are spontaneous arrhythmias. Finally, pacing-related ventricular deterioration is possible, with an increase in ventricular arrhythmias. 28 The possibility that the device could be proarrhythmic also has been analyzed on clinical grounds. We recently evaluated the results of several randomized ICD trials (primary and secondary prevention) and compared the appropriate ICD therapies with SCD in the control group as an arrhythmic manifestation. 29 In all studies, a Ͼ2-fold increase was present in arrhythmic events in the ICD group. Because patients with tolerated VT typically have sustained episodes, one could not assume that the device was just "oversensing" episodes that would have terminated spontaneously. Ellenbogen et al 30 performed an elegant analysis on data from a randomized ICD trial in patients with dilated cardiomyopathy and low ejection fractions (the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation [DEFINITE] trial). These investigators hypothesized that because patient allocation was random, spontaneous arrhythmic mortality should have been essentially the same in both groups. Thus, if appropriate ICD shocks were a reliable surrogate for arrhythmic death, appropriate ICD shocks plus SCD in the ICD group would have equaled SCD (arrhythmic death) in the standard therapy group. However, the number of appropriate ICD shocks (nϭ33) was more than double the number of arrhythmic deaths in the conventional arm (nϭ15), providing evidence that "counting (appropriate) ICD shocks is not equivalent to counting lives saved by ICD therapy." 30 These data are Single-lead ECG continuous recordings showing the last 3 ICD discharges during a spontaneous episode of an initially sustained nonsyncopal monomorphic VT in a patient admitted for syncope after repetitive ICD discharges. In the top tracing, an ICD discharge delivered during a monomorphic VT results in VF. The second tracing shows that another ICD discharge delivered during VF results in a monomorphic VT with a different morphology. The third tracing shows that another shock during this VT results in VF. Because this was the last ICD shock, the patient remains in VF until the medical personnel delivered an external shock 25 seconds later. The patient never had syncope or arrest before ICD implantation despite several episodes of monomorphic VT. Had the ICD not been in place, the patient probably would have sought medical attention without experiencing a cardiac arrest. similar to the data of Germano et al. 29 Somewhat similar observations have been made in at least 2 studies involving VT ablation; patients with an ICD implanted had more VT recurrences than those without an ICD (see below). 31, 32 In one of these studies, having an ICD implanted was shown to be an independent predictor of VT recurrence. 31 Two conclusions can be reached from these studies. First, it seems unjustified to infer clinical consequences (ie, prognosis or probability of recurrence) to a general VT population from the recorded ICD electrograms from those who had the device implanted. Second, the ICD could be producing arrhythmias that it then treats, leading to both an assumed higher incidence of spontaneous arrhythmias and an imagined efficacy.
VT Surgery as a Model For Substrate Ablation: Reduction of VT Recurrences and SCD
VT surgery was actively performed at a number of centers in the 1980s when the use of ICDs was limited and catheter ablation for VT was nonexistent. Unfortunately, use of this procedure has nearly vanished because of its relatively high operative mortality and complexity compared with ICD implantation and catheter ablation. However, the results of a combined series of 3 centers showed that SCD in 229 patients rendered noninducible after VT surgery was as low as 4% after a 5-year follow-up. 33 In a follow-up of patients undergoing surgical ablative therapy for tolerated and untolerated VT at the University of Pennsylvania, the incidence of SCD was 4% over 5 years and was 0% in patients with singlevessel disease (unpublished observations). As stated earlier, these patients still have a considerable mortality as a result of heart failure. VT surgery included revascularization in a significant number of patients (61% in the Pennsylvania series 34 ), and it could be suggested that revascularization was the curative mechanism. However, the poor results of previous series including revascularization alone or with aneurysmectomy 33 along with the scar nature of the VT substrate suggest that revascularization is not the main mechanism of benefit of surgical techniques. Thus, the high antiarrhythmic efficacy of surgical ablative techniques can be regarded as proof of concept for all ablative therapies in the sense that removing the substrate not only suppresses VT recurrence but also lowers arrhythmic mortality in the absence of an increase in the contractile muscle mass and without the improvements in pharmacological therapy developed in subsequent years.
Antiarrhythmic Drug Therapy for Ventricular Arrhythmias
The above discussion about the clinical outcome of patients with tolerated VT applies mostly to patients treated with antiarrhythmic drugs and to relatively old series. Three main messages have evolved in recent years in regard to antiarrhythmic drug therapy for ventricular arrhythmias. First, certain drugs such as sotalol, azimilide, and amiodarone can significantly decrease the number of ICD-treated ventricular arrhythmias, demonstrating that they in fact have some antiarrhythmic effects. [35] [36] [37] Second, in contrast, amiodarone, the most popular drug for ventricular arrhythmias, has repeatedly failed to decrease total mortality in patients with structural heart disease with or without heart failure. 38, 39 Third, compared with ICD therapy, amiodarone provided worse results in terms of total mortality as both primary prevention 40 and secondary prevention in patients having a variety of ventricular tachyarrhythmias except tolerated sustained VT 1,2 ; sotalol was shown to be of no practical use in a general way because in the AVID trial it was used in only 2% of the group assigned to drug therapy. 1 Although none of these messages apply specifically to patients with tolerated VT, they certainly would suggest more efficacy in decreasing number of episodes than in reducing the SCD rate.
Catheter Ablation Abolishing VT
For more than a decade, radiofrequency catheter ablation has been used to abolish postinfarction VT. Several groups have reported their experience, in most cases as a single-center experience, 31, 32, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] in an observational format, including cases in which the clinically documented VT could be induced and mapped during electrophysiological evaluation. These studies are summarized in the Table, totaling 735 patients in whom post-MI VT ablation was attempted.
Short-Term Results
Some differences exist in the ways in which different groups define whether the procedure has achieved short-term success. In general, if the VTs that were induced, mapped, and terminated during radiofrequency application could not be induced afterward, the procedure was considered successful. Some groups added the requirement for noninducibility in a second evaluation a few days after the ablation procedure. A matter of controversy has been the significance of additional VT morphologies different from the clinically documented VT. A full discussion of this subject is beyond the scope of this article. We will say only that in most of these studies, success has referred only to the VTs that were treated with ablation, and nonclinical VT morphologies were approached only if hemodynamically tolerated. If we accept the criteria for success used in each of the studies referred to in the Table, the short-term success rate was 76% if those studies are pooled together. 31, 32, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Major complications ranged from 0% to 15%, with an average of 6%, including a mortality rate that averaged 1.5% (Table) . Although these figures are by no means insignificant, they have to be considered in light of the low LV ejection fraction of the patients in these series (Table) and, perhaps most important, in light of the inclusion of patients in incessant VT and poor clinical condition in whom procedural risk is highest. 48, 49 
Long-Term Results
Most of these series have a mean follow-up that extends for Ͼ1 year, and some of them extend their mean follow-up for Ն3 years. If all patients submitted to an ablation attempt are considered on an intention-to-treat principle, the probability of a recurrence of a sustained VT during follow-up is significant at a mean value of 33% (Table) . However, most investigators 49, 50 have found that the short-term response is predictive of the long-term outcome. In addition, in all series, a large proportion of patients had ICDs implanted (Table) , particularly those patients in whom the procedure was thought to be unsuccessful, and in these patients, recurrences had to be assessed by the stored electrograms retrieved from the device with the limitations discussed above.
Moreover, it has been shown that VT recurrences are significantly more frequent in patients who have an ICD after VT ablation. 31, 32 It could be argued that the investigators chose to implant an ICD after ablation in patients who were more likely to have VT recurrences, but it has been shown that the implantation of an ICD is an independent predictor of VT recurrence after VT ablation, 31 raising the alternative explanation, as discussed above, that the ICD may in fact be arrhythmogenic in these patients. A third potential explanation is misclassification of nonsustained VT as sustained because the device provided therapy, but we feel that this is unlikely on a significant scale because patients suffering from sustained VT tend to recur with sustained VT. As shown in Figure 2 , the overwhelming majority of VT recurrences occurred in patients with an ICD implanted. In this study, with a 46% recurrence rate in the total population, those without an ICD had Ͻ10% recurrence rate. It is of note that 106 of the 115 ICDs implanted in this study had been implanted before the ablation procedure, thus excluding a bias in the postablation ICD indication as an explanation for the higher recurrence rate in ICD patients. For these reasons, a search was made through each study in the Table to detect the proportion of patients having VT recurrences and/or SCD among those who had a procedure with short-term success and no ICD implanted. The VT recurrence rate in 286 such patients was 14%, less than half that in the total population. However, the most striking finding in these people is the low SCD rate of 2.5% among 319 patients (Table) .
Summary of Published Results in Patients Undergoing Catheter Ablation of Post-MI VT
Additional information comes from patients having an ICD before the ablation procedure in whom the indication for ablation comes from the intolerable number of ICD shocks. In these patients, the arrhythmic activity can be judged quantitatively and in a similar fashion before and after ablation by the number of ICD therapies. A successful ablation procedure dramatically decreased ICD therapies 32,51 from a mean of 60 therapies per month before ablation to a mean of 0.1 therapies per month after ablation. 51 Interestingly, ICD therapies decreased even when the procedure was thought to be unsuccessful. 51 The above studies, although not controlled, strongly suggest that ablation therapy can be efficacious in most tolerated post-MI VT patients and that this can be predicted by the short-term result. Most important, they show that although recurrences can occur, SCD risk is quite low if the ablation procedure is successful in the short term.
Catheter Ablation of the VT Substrate
It is clear that both the need for inducibility of the clinical arrhythmia 52 and the need for clinical tolerance to allow mapping limit the proportion of patients amenable to VT ablation if energy application has to be delivered during ongoing VT. 53 The introduction in clinical practice of a number of nonfluoroscopic navigation systems and the recognition of additional criteria to identify the substrate 54 -56 have allowed more precise identification of the VT substrate and consequently ablation of VT during sinus rhythm. Since the pioneer work of Marchlinski et al, 57 several other groups have used a variety of criteria to recognize and ablate the substrate, reporting good results and creating the expectation that an ablation approach also can be offered to post-MI VT patients in a more general fashion. 58 -64 Very recently, the results of the first randomized controlled trial involving catheter ablation for ventricular arrhythmias have been presented, so far only as an abstract. 65 This interesting trial randomized 126 ICD candidates to undergo or not undergo a substrate ablation procedure in addition to conventional therapy, including the ICD. During a follow-up of 24 months, the ablation group had a significant decrease in appropriate ICD therapies (31% versus 15%) and appropriate shocks (24% versus 8%), with a tendency (nonsignificant) toward a decrease in total mortality (17% versus 8%). This randomized controlled trial, along with previous work, provides support for the concept that catheter ablation approaching the arrhythmia substrate is an efficacious protection against ventricular arrhythmias.
SCD and Complications in Patients
With an ICD ICDs have been proved to be efficacious to decrease SCD and total mortality in patients at a risk of SCD. However, despite the tendency to believe that they offer complete protection against arrhythmic death, SCD can occur in ICD-treated patients. 7, 21, 66 In a controlled randomized trial that included patients with coronary artery disease and a similar degree of LV dysfunction that had SCD or cardiac arrest as its main end point with a blinded assignment of mode of death, the 3-year actuarial incidence of cardiac arrest/SCD in the ICD group was 6%, 67 certainly not lower than the 2.5% found in successfully ablated patients. It could be argued that even that 2.5% SCD rate could have been decreased further with the ICD. However, this should be balanced against the risks related to ICD therapy. Although some clinical trials have reported up to Ͼ800 ICD implants without operative mortality, 39,68 a prospective multicenter trial from the late 1990s that included 778 patients 69 and a recent study reporting on 30 984 unselected patients implanted with an ICD in 2003 70 observed an almost 1% operative mortality. This operative mortality increased to 1.1% in the case of resynchronization therapy. 70 Significant complications of ICD therapy are invariably reported even in recent series, ranging from 3% in clinical trials with short follow-up 68 to 31% in a single-center prospective experience with a mean follow-up of almost 4 years. 71 In the Medicare population of 30 984 patients, the acute complication rate was 10.8%. 70 Moreover, some studies have found that among ICD patients, those having therapies (shocks in some studies) have higher mortality. 66, 72, 73 Although patients having shocks may be sicker, in a subanalysis from the Multicenter Automatic Defibrillator Trial II (MADIT-II), 66 only marginal differences existed between patients having and not having ICD therapies (shocks in 144 of 169 VT patients), and prognosis was worse for the former, suggesting the alternative hypothesis that ICD shocks could be harmful. Additional support for this idea comes from the observations in several studies that patients having frequent shocks (in the form of electrical storm or multiple consecutive discharges) have a poor prognosis. 74 -77 The long-term effects of the not-so-infrequent lead complications, leading to inappropriate shocks and proarrhythmia, may add to the ICD risk, 27 making ICD therapy even less attractive for a population with severe structural heart disease but low SCD risk. In addition, it has been demonstrated that both adverse symptoms and ICD shocks decrease the quality of life 78 in ICD patients, an important consideration in a patient population likely to experience ICD shocks. In contrast, quality of life improves in ICD recipients experiencing frequent shocks after a successful ablation procedure but not after an unsuccessful ablation. 51 Probably because of all the above considerations, in the recently published American College of Cardiology/American Heart Association Task Force/European Society of Cardiology guidelines, the therapeutic indications in patients with post-MI VT (both ICD and catheter ablation) have a level of evidence C. 79 
Final Considerations
Despite our limited knowledge about the outcome of patients with tolerated post-MI VT, the information available at the present time suggests that catheter ablation, if successful in the short term, confers both qualitative and quantitative protection against VT recurrence and SCD. Of note, although recurrence of a tolerated VT is not so rare, the SCD rate in these patients is extremely low. The recently introduced technique of substrate ablation for untolerated VT offers ablative options to a more general post-MI VT population and has been shown in a randomized controlled trial to decrease ICD therapies and shocks. Thus, catheter ablation can be considered a therapeutic alternative for those patients with post-MI tolerated VT in whom the procedure produces a satisfactory short-term result. The virtual absence of SCD in patients with tolerated VT and single-vessel disease makes such patients ideal candidates for ablation as a first-line therapy. 
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